Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Go Capital

Investor type Private Equity Firm

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 89
Average round size
info
The average size of a deal this fund participated in
$7M
Portfolio companies 67
Rounds per year 4.68
Lead investments 20
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.25
Exits 5
Key employees Soon
Stages of investment
Early Stage Venture
Private Equity
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Software
  • Medical Device
  • Medical

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Go Capital:
Typical Co-investors
Go Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Go Capital:

Funds with similar focus

Funds from France
Funds with similar focus located in France:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Graftys

Biotechnology
Fitness
Health Care
Wellness
$2M19 Jul 2022 Aix-en-Provence, Provence-Alpes-Côte d'Azur, France

Healshape

3D Printing
Biotechnology
$7M28 Jun 2022 Villeurbanne, Rhone-Alpes, France

Pepette

Pet
$6M21 Jun 2022 Paris, Ile-de-France, France

Pubstack

Information Technology
Software
$6M22 Mar 2022 Paris, Ile-de-France, France

LeddarTech

Automotive
Autonomous Vehicles
Hardware
Manufacturing
Software
$116M03 Feb 2022 Quebec City, Quebec, Canada

Secure-IC

Consumer Electronics
Information Technology
Virtual Reality
$23M20 Jan 2022 Bretagne, Brittany, France

Aurora Cold Plasma Sterilisation

Biopharma
Biotechnology
Professional Services
$3M10 Dec 2021 France, Idaho, United States

Shopopop

E-Commerce
Logistics
$23M05 Dec 2021 Nantes, Pays de la Loire, France

Ayro

Industrial Engineering
Industrial Manufacturing
Mechanical Engineering
$12M13 Sep 2021 Paris, Ile-de-France, France
News
Coave Therapeutics Closes €33M in Series B Financing

– Coave Therapeutics, a Paris, France-based clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, raised a €21.2m ($25.1m) expansion of its Series B funding round, bringing the total raised to €33.1m ($39m).
– This round was led by Seroba Life Sciences, supported by new investors Théa Open Innovation and eureKARE alongside existing shareholders Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital, and Sham Innovation Santé/Turenne.
– The company will use the proceeds to support the execution of its corporate strategy, which is focused on advancing its lead clinical program CTx-PDE6b for the treatment of PDE6b inherited retinal dystrophies, currently in Phase I/II clinical trial, towards pivotal trials, developing its AAV Ligand Conjugate (‘ALIGATER’) platform, which is designed to enhance the delivery and efficiency of AAV vectors via a proprietary chemical conjugation technology to produce targeted gene therapy products, advancing new preclinical programs, based on AAV-Ligand Conjugate capsids (coAAV), in rare CNS and Ocular diseases, including CTx-GBA1 for Parkinson’s disease and Gaucher Disease and CTx-ABCA4 for Stargardt’s disease, entering partnerships in key disease areas to progress novel coAAV candidates towards the clinic and to address other disease areas given the potential of the platform and the scope for targeting other tissues.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Go Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: